ArticleEuropean journal of neurology2025
Markers of Giant Cell Arteritis in Patients Presenting With Ischemic Stroke: A Scoping Review.
Article in European journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Risk factors for acute coronary syndrome in patients with giant cell arteritis: a scoping review.Therapeutic advances in musculoskeletal disease · 2026Article
- Markers of Giant Cell Arteritis in Patients Presenting With Ischemic Stroke: A Scoping Review.European journal of neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn patients with giant cell arteritis (GCA), 2.8%-8.2% present with ischemic stroke (IS) or transient ischemic attack (TIA). GCA diagnosis may be overlooked, and immunosuppressive treatment delayed if typical symptoms are absent or if a common cause of IS coexists. This study aimed to identify potential markers of GCA through clinical evaluation and baseline investigation of IS/TIA patients.
methodsTwo authors independently conducted a scoping review using MEDLINE and EMBASE databases to identify patients diagnosed with GCA after presenting with IS/TIA. All articles, including the gray literature, were considered from January 2000 onwards if individualized data were described. Only cases of IS/TIA with GCA later diagnosed as the etiology were included for analysis.
resultsA total of 101 publications were included, pooling data on 141 patients for analysis. The mean age was 73.6 years, and 61 were women. Patients experienced either single (56.0%) or multiple IS/TIA events (44.0%). Associated symptoms included GCA-related pain, such as headaches (50.4%), constitutional symptoms (47.5%), and temporal artery inflammation (27.0%). Neurological deficits involved corticospinal tracts (41.8%), and cerebellar functions (53.2%). Most patients had clinical or radiological evidence of vertebrobasilar involvement (83.7%). Multifocal involvement of the vertebrobasilar and carotid territories was supported when combining clinical-radiological manifestations (41.1%). Recurrent events were common (44.0%).
conclusionGCA should be considered in IS/TIA patients aged ≥ 50 years with vertebrobasilar or multiterritorial involvement, or recurrent IS/TIA despite secondary prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.